ATAD1 and infectious disease: This highly immunogenic subunit vaccine delivery platform has undergone recent clinical development for a range of difficult infectious disease targets,45,46 and these vaccine candidates were previously reported to induce high levels of antigen-specific T cells as well as substantial serum IgG antibody responses in healthy adult UK volunteers.28,29 Here, we showed that antigen-specific mBC responses were primed and boosted against both antigens following ChAd63-MVA MSP1 or AMA1 vaccination.